TAKESHIA NIDAY: Open Payments
NPI 1932429289 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,291 in 60 payments from 12 companies in 2025. Trend: 2023 $839 · 2024 $1,966 · 2025 $2,291
Food & beverage: $2,291
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $523 |
| Alkermes, Inc. | 6 | $346 |
| Otsuka America Pharmaceutical, Inc. | 11 | $325 |
| Teva Pharmaceuticals USA, Inc. | 6 | $292 |
| E.R. Squibb & Sons, L.L.C. | 4 | $214 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 6 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $121 |
| ABBVIE INC. | 3 | $84 |
| Lundbeck LLC | 3 | $76 |
| Janssen Pharmaceuticals, Inc | 2 | $60 |
Products named: INGREZZA, REXULTI, ARISTADA, COBENFY, UZEDY, LYBALVI, CAPLYTA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
